Share on StockTwits

Veracyte (NASDAQ:VCYT) Insider Christopher M. Hall sold 2,000 shares of Veracyte stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $16.95, for a total value of $33,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday. They set an “overweight” rating and a $21.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $20.50.

Shares of Veracyte (NASDAQ:VCYT) traded up 3.38% on Monday, hitting $16.82. The stock had a trading volume of 211,405 shares. Veracyte has a 52-week low of $10.88 and a 52-week high of $19.00. The stock has a 50-day moving average of $14.2 and a 200-day moving average of $14.93. The company’s market cap is $356.1 million.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter last year, the company posted ($9.04) earnings per share. Veracyte’s revenue was up 70.5% compared to the same quarter last year. Analysts expect that Veracyte will post $-1.31 EPS for the current fiscal year.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.